Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-masked Study With Intraocular Anti-VEGF (Avastin/Lucentis) Compared With Intraocular Triamcinolone (Volon A) in Patients With Clinical Significant Diabetic Macular Edema

Next Previous
Trial Profile

A Randomized, Double-masked Study With Intraocular Anti-VEGF (Avastin/Lucentis) Compared With Intraocular Triamcinolone (Volon A) in Patients With Clinical Significant Diabetic Macular Edema

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 09 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bevacizumab (Primary) ; Ranibizumab (Primary) ; Triamcinolone
  • Indications Diabetic macular oedema
  • Focus Therapeutic Use
  • Acronyms TRIASTIN

Most Recent Events

  • 01 Jan 2018 Results (n=25) of post hoc analysis of morphologic characteristics in OCT, FA and CF images assessing the effect of ranibizumab vs triamcinolone on changes in retinal morphology published in the Graefes Archive for Clinical and Experimental Ophthalmology
  • 03 Mar 2016 Status changed from recruiting to completed, according to ClinicalTrials.gov record.
  • 31 May 2013 Planned end date changed from 1 Oct 2009 to 1 Dec 2014 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top